Daniel E. Speiser
Clinical Investigation Center
Ludwig Institute for Cancer Research Ltd.
Lausanne branch
University of Lausanne
Switzerland
Name/email consistency: high
- Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Speiser, D.E., Romero, P. Semin. Immunol. (2010)
- Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. Speiser, D.E., Schwarz, K., Baumgaertner, P., Manolova, V., Devevre, E., Sterry, W., Walden, P., Zippelius, A., Conzett, K.B., Senti, G., Voelter, V., Cerottini, J.P., Guggisberg, D., Willers, J., Geldhof, C., Romero, P., Kündig, T., Knuth, A., Dummer, R., Trefzer, U., Bachmann, M.F. J. Immunother. (2010)
- Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Speiser, D.E., Baumgaertner, P., Voelter, V., Devevre, E., Barbey, C., Rufer, N., Romero, P. Proc. Natl. Acad. Sci. U.S.A. (2008)
- Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. Speiser, D.E., Liénard, D., Rufer, N., Rubio-Godoy, V., Rimoldi, D., Lejeune, F., Krieg, A.M., Cerottini, J.C., Romero, P. J. Clin. Invest. (2005)
- Toward improved immunocompetence of adoptively transferred CD8+ T cells. Speiser, D.E., Romero, P. J. Clin. Invest. (2005)
- Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring. Speiser, D.E., Pittet, M.J., Guillaume, P., Lubenow, N., Hoffman, E., Cerottini, J.C., Romero, P. J. Immunother. (2004)
- Disease-driven T cell activation predicts immune responses to vaccination against melanoma. Speiser, D.E., Rimoldi, D., Batard, P., Liénard, D., Lejeune, F., Cerottini, J.C., Romero, P. Cancer Immun. (2003)
- Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Speiser, D.E., Pittet, M.J., Rimoldi, D., Guillaume, P., Luescher, I.F., Liénard, D., Lejeune, F., Cerottini, J.C., Romero, P. Semin. Cancer Biol. (2003)
- In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Speiser, D.E., Liénard, D., Pittet, M.J., Batard, P., Rimoldi, D., Guillaume, P., Cerottini, J.C., Romero, P. Eur. J. Immunol. (2002)
- Can hTERT peptide (540-548) -specific CD8 T cells recognize and kill tumor cells?. Speiser, D.E., Cerottini, J.C., Romero, P. Cancer Immun. (2002)
- The activatory receptor 2B4 is expressed in vivo by human CD8+ effector alpha beta T cells. Speiser, D.E., Colonna, M., Ayyoub, M., Cella, M., Pittet, M.J., Batard, P., Valmori, D., Guillaume, P., Liénard, D., Cerottini, J.C., Romero, P. J. Immunol. (2001)
- CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. Speiser, D.E., Valmori, D., Rimoldi, D., Pittet, M.J., Liénard, D., Cerundolo, V., MacDonald, H.R., Cerottini, J.C., Romero, P. Eur. J. Immunol. (1999)
- In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. Speiser, D.E., Pittet, M.J., Valmori, D., Dunbar, R., Rimoldi, D., Liénard, D., MacDonald, H.R., Cerottini, J.C., Cerundolo, V., Romero, P. J. Exp. Med. (1999)